TY - JOUR
T1 - Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma
AU - Fiumicino, S.
AU - Ercoli, A.
AU - Ferrandina, G.
AU - Hess, P.
AU - Raspaglio, G.
AU - Genuardi, M.
AU - Rovella, V.
AU - Bellacosa, A.
AU - Cicchillitti, L.
AU - Mancuso, S.
AU - Bignami, M.
AU - Scambia, G.
PY - 2001/2/15
Y1 - 2001/2/15
N2 - Purpose: The aim of this study was to define the prognostic role of microsatellite status in 65 stage I-II primary sporadic endometrioid endometrial adenocarcinoma (EEA) patients. Patients and Methods: Familiarity for neoplasia was ascertained in all patients on the basis of a questionnaire. Microsatellite status was assessed by matching normal and tumoral DNA probed for five dinucleotide repeats and one mononucleotide repeat marker. Microsatellite status was analyzed in relation to clinicopathologic characteristics of the patients and length of disease-free survival (DFS). Results: Eleven tumors (17%) of 65 had instability at two or more loci and were considered as unstable or microsatellite instabillity (MI). Tumors with no instability or instability at one locus were classified as microsatellite stable (MS). The percentage of MI was significantly higher in poorly than in well to moderately differentiated tumors (50% v 9%; P = .003). The 5-year DFS rate of MI patients was 65% (95% confidence interval [CI], 35% to 91%) versus 9G% (95% CI, 91% to 101%) of MS patients (P = .0004). In multivariate analysis, only the presence of MI, stage II of disease, and depth of myometrial invasion greater than 50% retained independent pragnostic roles. Conclusion: The assessment of microsatellite status may provide useful information for preoperative prognostic characterization of stage I-II primary sporadic EEA patients in which more individualized treatment options can be attempted.
AB - Purpose: The aim of this study was to define the prognostic role of microsatellite status in 65 stage I-II primary sporadic endometrioid endometrial adenocarcinoma (EEA) patients. Patients and Methods: Familiarity for neoplasia was ascertained in all patients on the basis of a questionnaire. Microsatellite status was assessed by matching normal and tumoral DNA probed for five dinucleotide repeats and one mononucleotide repeat marker. Microsatellite status was analyzed in relation to clinicopathologic characteristics of the patients and length of disease-free survival (DFS). Results: Eleven tumors (17%) of 65 had instability at two or more loci and were considered as unstable or microsatellite instabillity (MI). Tumors with no instability or instability at one locus were classified as microsatellite stable (MS). The percentage of MI was significantly higher in poorly than in well to moderately differentiated tumors (50% v 9%; P = .003). The 5-year DFS rate of MI patients was 65% (95% confidence interval [CI], 35% to 91%) versus 9G% (95% CI, 91% to 101%) of MS patients (P = .0004). In multivariate analysis, only the presence of MI, stage II of disease, and depth of myometrial invasion greater than 50% retained independent pragnostic roles. Conclusion: The assessment of microsatellite status may provide useful information for preoperative prognostic characterization of stage I-II primary sporadic EEA patients in which more individualized treatment options can be attempted.
KW - Adaptor Proteins, Signal Transducing
KW - Adenocarcinoma/genetics
KW - Age Factors
KW - Carrier Proteins
KW - Endometrial Neoplasms/genetics
KW - Female
KW - Humans
KW - Microsatellite Repeats/genetics
KW - Middle Aged
KW - Multivariate Analysis
KW - MutL Protein Homolog 1
KW - Neoplasm Proteins/analysis
KW - Neoplasm Recurrence, Local
KW - Nuclear Proteins
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=0035865155&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000167219400012&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1200/JCO.2001.19.4.1008
DO - 10.1200/JCO.2001.19.4.1008
M3 - Article
C2 - 11181663
SN - 0732-183X
VL - 19
SP - 1008
EP - 1014
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 4
ER -